219 related articles for article (PubMed ID: 27103006)
1. A rare composite lymphoma: follicular and in situ mantle cell.
Marí-Jimenez P; Martínez-Losada C; Centeno-Haro M; Rodríguez-García G; Perez-Seoane C; Sánchez-García J
Ann Hematol; 2016 Aug; 95(8):1351-2. PubMed ID: 27103006
[No Abstract] [Full Text] [Related]
2. [Composite lymphoma cosisting of mantle cell lymphoma and follicular lymphoma].
Matsuoka A; Tsushima T; Tanibuchi M; Katsuki N; Kushida Y; Takata K; Taoka T
Rinsho Ketsueki; 2013 Nov; 54(11):2056-61. PubMed ID: 24305539
[TBL] [Abstract][Full Text] [Related]
3. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
4. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
[No Abstract] [Full Text] [Related]
5. Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.
Lamm W; Kiesewetter B; Puhr H; Dolak W; Mayerhöfer ME; Raderer M
Ann Hematol; 2019 Jun; 98(6):1519-1520. PubMed ID: 30547188
[No Abstract] [Full Text] [Related]
6. Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
Zoellner AK; Weiglein T; Hutter G; Zimmermann Y; Cieplik HC; Hess G; Dreyling M
Ann Hematol; 2016 Feb; 95(3):403-7. PubMed ID: 26658770
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Gyan E; Sonet A; Brice P; Anglaret B; Laribi K; Fruchart C; Tilly H; Araujo C; Soubeyran P; Gonzalez H; Morineau N; Nicolas-Virelizier E; Ghesquières H; Salles B; Bouabdallah R; Orfeuvre H; Fahri J; Couturier O; Xerri L; Feugier P;
Br J Haematol; 2018 Oct; 183(1):76-86. PubMed ID: 30117149
[TBL] [Abstract][Full Text] [Related]
9. Orbital soft tissue composite lymphoma presenting as recurrence of a nodal lymphoma with mantle and follicular cell components: A case report, literature review and guideline for the treatment of patients.
Sabater-Marco V; Santonja-López N; Ortíz-Zuluaga S; Navarro-Cerveró L; Orero-Castelló MT
Rev Esp Patol; 2020; 53(1):48-54. PubMed ID: 31932010
[TBL] [Abstract][Full Text] [Related]
10. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.
Kamdar M; Li H; Chen RW; Rimsza LM; Leblanc ML; Fenske TS; Shea TC; Barr PM; Phillips TJ; Leonard JP; Kahl BS; Friedberg JW; Smith SM
Blood Adv; 2019 Oct; 3(20):3132-3135. PubMed ID: 31648328
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA
Leuk Lymphoma; 2017 Jul; 58(7):1589-1597. PubMed ID: 27838951
[TBL] [Abstract][Full Text] [Related]
12. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
[No Abstract] [Full Text] [Related]
13. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
[No Abstract] [Full Text] [Related]
14. [Composite lymphoma: Case report of a coexisting follicular and mantle cell lymphoma in situ in a cervical node].
Linard C; Lasne-Cardon A; Salaun V; Rousselot P; Dorbeau M
Ann Pathol; 2022 Mar; 42(2):177-182. PubMed ID: 34949480
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
[TBL] [Abstract][Full Text] [Related]
16. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
Albertsson-Lindblad A; Palsdottir T; Smedby KE; Weibull CE; Glimelius I; Jerkeman M
Haematologica; 2022 Mar; 107(3):740-743. PubMed ID: 34788983
[No Abstract] [Full Text] [Related]
17. Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein-Barr virus-positive follicular lymphoma.
Miyazawa Y; Yokohama A; Ishizaki T; Tsukamoto N; Koshi H; Hirato J; Handa H
Int J Hematol; 2021 Apr; 113(4):592-599. PubMed ID: 33387297
[TBL] [Abstract][Full Text] [Related]
18. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
[No Abstract] [Full Text] [Related]
19. [New data prove therapeutic superiority. MabThera in follicular and mantle cell lymphoma].
Krankenpfl J; 2002; 40(5-6):161. PubMed ID: 12271501
[No Abstract] [Full Text] [Related]
20. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]